These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

570 related articles for article (PubMed ID: 17288531)

  • 1. Key roles of the OPG-RANK-RANKL system in bone oncology.
    Baud'huin M; Duplomb L; Ruiz Velasco C; Fortun Y; Heymann D; Padrines M
    Expert Rev Anticancer Ther; 2007 Feb; 7(2):221-32. PubMed ID: 17288531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling.
    Theoleyre S; Wittrant Y; Tat SK; Fortun Y; Redini F; Heymann D
    Cytokine Growth Factor Rev; 2004 Dec; 15(6):457-75. PubMed ID: 15561602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biology of RANK, RANKL, and osteoprotegerin.
    Boyce BF; Xing L
    Arthritis Res Ther; 2007; 9 Suppl 1(Suppl 1):S1. PubMed ID: 17634140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The role of RANK/RANKL/osteoprotegerin (OPG) triad in cancer-induced bone diseases: physiopathology and clinical implications].
    Clézardin P
    Bull Cancer; 2011 Jul; 98(7):837-46. PubMed ID: 21700551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RANK/RANKL/OPG role in distraction osteogenesis.
    Pérez-Sayáns M; Somoza-Martín JM; Barros-Angueira F; Rey JM; García-García A
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 May; 109(5):679-86. PubMed ID: 20163972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The OPG/RANKL/RANK system and bone resorptive disease].
    Liu JZ; Ji ZL; Chen SM
    Sheng Wu Gong Cheng Xue Bao; 2003 Nov; 19(6):655-60. PubMed ID: 15971575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The RANK/RANKL/OPG triad in cancer-induced bone diseases.
    Dougall WC; Chaisson M
    Cancer Metastasis Rev; 2006 Dec; 25(4):541-9. PubMed ID: 17180711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Osteoporosis and aterosclerosis--is there any pathogenetic association?].
    Zofková I
    Cas Lek Cesk; 2007; 146(3):246-50. PubMed ID: 17419308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease.
    D'Amelio P; Isaia G; Isaia GC
    J Endocrinol Invest; 2009; 32(4 Suppl):6-9. PubMed ID: 19724159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteoprotegerin/RANK/RANKL axis in cardiac remodeling due to immuno-inflammatory myocardial disease.
    Liu W; Feng W; Wang F; Li W; Gao C; Zhou B; Ma M
    Exp Mol Pathol; 2008 Jun; 84(3):213-7. PubMed ID: 18417124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
    Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
    Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
    Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
    Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis.
    Blair JM; Zhou H; Seibel MJ; Dunstan CR
    Nat Clin Pract Oncol; 2006 Jan; 3(1):41-9. PubMed ID: 16407878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas.
    Mikami S; Katsube K; Oya M; Ishida M; Kosaka T; Mizuno R; Mochizuki S; Ikeda T; Mukai M; Okada Y
    J Pathol; 2009 Aug; 218(4):530-9. PubMed ID: 19455604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis.
    Pettit AR; Walsh NC; Manning C; Goldring SR; Gravallese EM
    Rheumatology (Oxford); 2006 Sep; 45(9):1068-76. PubMed ID: 16490750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
    Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
    Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Genomic approaches to bone and joint diseases. Mutations of RANK, OPG and RANKL genes found in humans].
    Kobayashi Y; Takahashi N
    Clin Calcium; 2008 Feb; 18(2):202-9. PubMed ID: 18245890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RANKL signaling in bone physiology and cancer.
    Dougall WC
    Curr Opin Support Palliat Care; 2007 Dec; 1(4):317-22. PubMed ID: 18685382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Receptor activator of nuclear factor-kappaB ligand (RANKL) directly modulates the gene expression profile of RANK-positive Saos-2 human osteosarcoma cells.
    Mori K; Berreur M; Blanchard F; Chevalier C; Guisle-Marsollier I; Masson M; Rédini F; Heymann D
    Oncol Rep; 2007 Dec; 18(6):1365-71. PubMed ID: 17982618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wnt pathway and IL-17: novel regulators of joint remodeling in rheumatic diseases. Looking beyond the RANK-RANKL-OPG axis.
    Daoussis D; Andonopoulos AP; Liossis SN
    Semin Arthritis Rheum; 2010 Apr; 39(5):369-83. PubMed ID: 19095294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.